Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Epsilon Healthcare Limited ( (AU:EPN) ) has shared an update.
Epsilon Healthcare’s wholly owned subsidiary Epsilon Pharma has secured Halal Australia certification for its CBD and THC oil dosage forms, confirming that its Australian manufacturing operations meet stringent Halal requirements and comply with the GSO/UAE.S 2055-1 standard for handling, processing, storage and distribution. The accreditation is positioned as a key endorsement of the company’s advanced, compliant manufacturing capabilities and is expected to open access to Halal-regulated markets in the Middle East, Southeast Asia and other regions, supporting new international partnerships, expansion into Halal-compliant markets and long-term strategic growth in premium regulated product segments.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
More about Epsilon Healthcare Limited
Epsilon Healthcare Limited is an Australian medical cannabis company that operates through its contract development and manufacturing arm, Epsilon Pharma Pty Ltd. The group specialises in the production of CBD and THC oil dosage forms from its onshore Queensland facilities, targeting regulated, premium segments of the global medicinal cannabis market, including regions with specific compliance requirements such as Halal standards.
YTD Price Performance: -3.03%
Average Trading Volume: 445,736
Technical Sentiment Signal: Buy
Current Market Cap: A$12.13M
For detailed information about EPN stock, go to TipRanks’ Stock Analysis page.